WCD 2019: Experimental Topical Tropomyosin Receptor Kinase A Inhibitor Improved Psoriasis Severity
Phase III trials are in the works, pending regulatory approval
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.